Results 101 to 110 of about 44,162 (208)

Combination treatment effects of BRAF (B-RAF proto-oncogene, serine/threonine kinase) inhibitors and HSP90 (heat shock protein 90) inhibitors in BRAF-mutated colorectal cancer cell lines

open access: yes
BRAFV600 Mutationen sind ein negativer Prognosefaktor beim kolorektalen Karzinom, welches typischerweise resistent gegen BRAF-Inhibitoren ist. Etliche Resistenzmechanismen sind HSP90-abhängig, sodass eine Kombination von BRAF- und HSP90-Inhibition einen vielversprechenden Ansatz darstellt. Allerdings ist die Datenlage bislang ungenügend.
openaire   +2 more sources

Expression of the oncogenes mil and ras abolishes the in vivo differentiation of mammary epithelial cells [PDF]

open access: yes, 2017
Three carcinoma-associated oncogenes, two of which have been strongly implicated in human mammary tumorigenesis, have been introduced into a novel mouse mammary epithelial cell line, EF43, that retains many differentiated functions.
Günzburg, Walter H.   +6 more
core  

The Drosophila MOS Ortholog Is Not Essential for Meiosis [PDF]

open access: yes, 2004
In metazoan oocytes, a metaphase arrest coordinates the completion of meiosis with fertilization. Vertebrate mos maintains the metaphase II arrest of mature oocytes and prevents DNA replication between the meiotic divisions.
Fenger, Douglas D.   +4 more
core   +1 more source

Whole‐genome CRISPR‐Cas9 knockout screens identify SHOC2 as a genetic dependency in NRAS‐mutant melanoma

open access: yes
Cancer Communications, EarlyView.
Andrea Y. Gu   +6 more
wiley   +1 more source

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation

open access: yesCancer Science, EarlyView.
We established a novel patient‐derived BRAF V600E‐mutated lung adenocarcinoma cell line and demonstrated that combining a novel TEAD1 inhibitor (VT103) with dabrafenib enhances therapeutic efficacy through survivin downregulation. Our tissue microarray analysis revealed a strong correlation between YAP1, TEAD1, and survivin expression in lung ...
Kazutaka Hosoya   +19 more
wiley   +1 more source

Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer

open access: yesCell Proliferation, EarlyView.
Lung cancer development involves mechanisms like reduced EGFR/EGF ubiquitination driving cancer cell behaviors and immune evasion via loss of PD‐1/PD‐L1 ubiquitination. Balancing ubiquitination and deubiquitination may be a potential therapeutic strategy. ABSTRACT Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
Guangyao Zhou   +5 more
wiley   +1 more source

Develop machine learning based predictive models for engineering protein solubility [PDF]

open access: yesarXiv, 2018
Protein activity is a significant characteristic for recombinant proteins which can be used as biocatalysts. High activity of proteins reduces the cost of biocatalysts. A model that can predict protein activity from amino acid sequence is highly desired, as it aids experimental improvement of proteins.
arxiv  

Immune checkpoint molecules and spatial transcriptome profiles according to BRAF status in acral melanoma

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The BRAF mutation in acral melanoma is associated with the expression of immune checkpoint molecules—PD‐1, LAG‐3 and TIM‐3—at both protein and mRNA levels. This suggests an association with the tumour microenvironment, including tumour‐associated immune cells, which influence both anti‐tumour immunity and tumour progression.
Hee Joo Yang   +6 more
wiley   +1 more source

Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes

open access: yesThe Journal of Pathology, Volume 266, Issue 3, Page 337-351, July 2025.
Abstract Pancreatic ductal adenocarcinomas (PDACs) with wild‐type KRAS constitute a small fraction of PDACs, and these tumors were recently shown to harbor frequent actionable oncogenic mutations and fusions. However, the clinicopathological features of KRAS wild‐type PDAC have not been well studied.
Kazuhiro Toriyama   +14 more
wiley   +1 more source

BRAF V600E Mutation in Odontogenic Keratocyst: A Systematic Review and Meta-Analysis

open access: yesPesquisa Brasileira em Odontopediatria e Clínica Integrada
Objective: To assess the frequency of the BRAF V600E mutation in odontogenic keratocyst, correlating the methods of evaluation and detection of the mutated protein.
Jéssica da Silva Cunha   +7 more
doaj  

Home - About - Disclaimer - Privacy